Fruquintinib plus paclitaxel has shown promising results as a second-line treatment option for patients with advanced gastric or gastroesophageal junction (GEJ) cancer. The combination improved responses and progression-free survival (PFS) compared to paclitaxel alone, and there was a trend toward improved overall survival (OS) with fruquintinib. The FRUTIGA trial included 703 patients with advanced gastric or GEJ adenocarcinoma, and patients who received fruquintinib had a median PFS of 5.6 months and an objective response rate of 42.5%. Treatment-emergent adverse events were higher in the fruquintinib arm, but investigators concluded that fruquintinib plus paclitaxel could be a promising second-line treatment option for these patients.
Source link
Adding Fruquintinib to Paclitaxel Improves PFS in Gastric, GEJ Cancer
